UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

The New England journal of medicine, 2020-01, Vol.382 (2), p.120-129

2020

Volltextzugriff (PDF)

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2018-01, Vol.391 (10117), p.219-229

2018

Volltextzugriff (PDF)

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2018-01, Vol.391 (10117), p.205-218

2018

Volltextzugriff (PDF)

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Circulation (New York, N.Y.), 2023-03, Vol.147 (13), p.1026-1038

2023

Volltextzugriff (PDF)

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures

Pharmacotherapy, 2022-10, Vol.42 (10), p.780-791

2022

Volltextzugriff (PDF)

The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis

Circulation (New York, N.Y.), 2024-04, Vol.149 (16), p.1315-1318

2024

Volltextzugriff (PDF)

The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy

British journal of haematology, 2024-08, Vol.205 (2), p.473-477

2024

Volltextzugriff (PDF)

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy

Cochrane database of systematic reviews, 2020-05, Vol.5 (5), p.CD005259

2020

Volltextzugriff (PDF)

Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review

American journal of health-system pharmacy, 2024-05, Vol.81 (11), p.e274-e282

2024

Volltextzugriff (PDF)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa

Journal of thrombosis and haemostasis, 2020-10, Vol.18 (10), p.2532-2541

2020

Volltextzugriff (PDF)

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis

Cochrane database of systematic reviews, 2023-04, Vol.4 (4), p.CD010956

2023

Volltextzugriff (PDF)

Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation

Journal of thrombosis and haemostasis, 2023-05, Vol.21 (5), p.1381-1384

2023

Volltextzugriff (PDF)

Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury

The Annals of pharmacotherapy, 2022-06, Vol.56 (6), p.656-663

2022

Volltextzugriff (PDF)

Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor–associated major bleeds

Thrombosis research, 2024-08, Vol.240, p.109046, Article 109046

2024

Volltextzugriff (PDF)

Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease

Journal of the American Heart Association, 2024-08, Vol.13 (16), p.e034641

2024

Volltextzugriff (PDF)

Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis

Texas Heart Institute journal, 2024-05, Vol.51 (1), p.1-7

2024

Volltextzugriff (PDF)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban

Journal of thrombosis and haemostasis, 2021-12, Vol.19 (12), p.3008-3017

2021

Volltextzugriff (PDF)

Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal

Clinical and applied thrombosis/hemostasis, 2024-01, Vol.30, p.10760296241243368-10760296241243368

2024

Volltextzugriff (PDF)

Efficacy and Safety of Direct Oral Anticoagulants for Acute Treatment of Venous Thromboembolism in Older Adults: A Network Meta-Analysis of Randomised Controlled Trials

Vascular and Endovascular Surgery, 2024-08, Vol.58 (6), p.633-639

2024

Volltextzugriff (PDF)

Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate

The American journal of emergency medicine, 2020-12, Vol.38 (12), p.2641-2645

2020

Volltextzugriff (PDF)

Rivaroxaban postmarketing risk of liver injury

Journal of hepatology, 2014-08, Vol.61 (2), p.293-300

2014

Volltextzugriff (PDF)

Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism

European journal of internal medicine, 2024-09, Vol.127, p.74-83

2024

Volltextzugriff (PDF)

Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re‐appraisal

Journal of thrombosis and haemostasis, 2015-06, Vol.13 (S1), p.S187-S194

Dzik, W. H.

2015

Volltextzugriff (PDF)

Comparison between use of direct oral anticoagulants and aspirin for risk of thromboembolism complications in patients undergoing total knee and hip arthroplasty: a systematic review and meta-analysis

European review for medical and pharmacological sciences, 2021-10, Vol.25 (20), p.6245

2021

Volltextzugriff (PDF)

Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA

International journal of laboratory hematology, 2022-02, Vol.44 (1), p.193-201

2022

Volltextzugriff (PDF)

1 – 25 von 652

Suche als RSS-Feed

Aktive Filter

ThemaFactor Xa Inhibitors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(599)
Mit Volltextzugriff
(427)

Publikationsform

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(623)
Science & Technology
(545)
Life Sciences & Biomedicine
(544)
Anticoagulants - Adverse Effects
(392)
Cardiovascular System & Cardiology
(274)
Anticoagulants - Therapeutic Use
(251)
Male
(241)
Hemorrhage - Chemically Induced
(226)
Female
(221)
Anticoagulants - Administration & Dosage
(206)
Administration, Oral
(201)
Peripheral Vascular Disease
(195)
Hematology
(189)
Biological And Medical Sciences
(181)
Medical Sciences
(181)
Rivaroxaban
(170)
Aged
(169)
Middle Aged
(164)
Anticoagulants
(161)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures

The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis

The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy

Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy

Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis

Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation

Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury

Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor–associated major bleeds

Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease

Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban

Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal

Efficacy and Safety of Direct Oral Anticoagulants for Acute Treatment of Venous Thromboembolism in Older Adults: A Network Meta-Analysis of Randomised Controlled Trials

Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate

Rivaroxaban postmarketing risk of liver injury

Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism

Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re‐appraisal

Comparison between use of direct oral anticoagulants and aspirin for risk of thromboembolism complications in patients undergoing total knee and hip arthroplasty: a systematic review and meta-analysis

Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA

Aktive Filter

Suchergebnisse filtern